Extended interval BNT162b2 vaccination enhances peak antibody generation

Helen Parry, Paul Moss, Christine Stephens, Christopher Bentley, Kevin Brown, Gayatri Amirthalingam, Bassam Hallis, Ashley Otter, Jianmin Zuo, Paul Moss

Research output: Contribution to journalArticlepeer-review

10 Downloads (Pure)

Abstract

The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies1. However, many countries extended this interval to accelerate population coverage with a single vaccine. It is not known how immune responses are influenced by delaying the second dose. We provide the assessment of immune responses in the first 14 weeks after standard or extended-interval BNT162b2 vaccination and show that delaying the second dose strongly boosts the peak antibody response by 3.5-fold in older people. This enhanced antibody response may offer a longer period of clinical protection and delay the need for booster vaccination. In contrast, peak cellular-specific responses were the strongest in those vaccinated on a standard 3-week vaccine interval. As such, the timing of the second dose has a marked influence on the kinetics and magnitude of the adaptive immune response after mRNA vaccination in older people.

Original languageEnglish
Article number14
JournalNPJ vaccines
Volume7
Issue number1
DOIs
Publication statusPublished - 27 Jan 2022

Bibliographical note

© 2022. The Author(s).

Fingerprint

Dive into the research topics of 'Extended interval BNT162b2 vaccination enhances peak antibody generation'. Together they form a unique fingerprint.

Cite this